1. Home
  2. GGR vs IMMP Comparison

GGR vs IMMP Comparison

Compare GGR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$4.01

Market Cap

83.3M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.44

Market Cap

76.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
IMMP
Founded
2011
1987
Country
Taiwan
Australia
Employees
1416
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
76.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
GGR
IMMP
Price
$4.01
$0.44
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
10.4K
871.1K
Earning Date
05-21-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.29
52 Week High
$6.21
$3.53

Technical Indicators

Market Signals
Indicator
GGR
IMMP
Relative Strength Index (RSI) 49.79 39.08
Support Level $3.93 $0.42
Resistance Level $4.33 $0.56
Average True Range (ATR) 0.20 0.03
MACD -0.02 0.01
Stochastic Oscillator 40.30 13.38

Price Performance

Historical Comparison
GGR
IMMP

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: